Open AccessDevelopment of Coagulation Factor XII Antibodies for Inhibiting Vascular Device-Related Thrombosis
Author(s) -
Tia C.L. Kohs,
Christina U. Lorentz,
Jennifer Johnson,
Cristina Puy,
Sven R. Olson,
Joseph J. Shatzel,
David Gailani,
Monica T. Hinds,
Erik I. Tucker,
András Gruber,
Owen J. T. McCarty,
Michael Wallisch
Publication year - 2020
Publication title -
cellular and molecular bioengineering
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.668
H-Index - 34
eISSN - 1865-5033
pISSN - 1865-5025
DOI - 10.1007/s12195-020-00657-6
Subject(s) - factor xii , coagulation , fibrin , thrombus , platelet activation , thrombosis , tissue factor , platelet , hemostasis , plasmin , chemistry , pharmacology , medicine , immunology , biochemistry , enzyme
Vascular devices such as stents, hemodialyzers, and membrane oxygenators can activate blood coagulation and often require the use of systemic anticoagulants to selectively prevent intravascular thrombotic/embolic events or extracorporeal device failure. Coagulation factor (F)XII of the contact activation system has been shown to play an important role in initiating vascular device surface-initiated thrombus formation. As FXII is dispensable for hemostasis, targeting the contact activation system holds promise as a significantly safer strategy than traditional antithrombotics for preventing vascular device-associated thrombosis.